Search

Your search keyword '"Mirallas O"' showing total 39 results

Search Constraints

Start Over You searched for: Author "Mirallas O" Remove constraint Author: "Mirallas O" Database ScienceDirect Remove constraint Database: ScienceDirect
39 results on '"Mirallas O"'

Search Results

3. 99P Molecular correlates and treatment outcomes of patients with brain metastasis included in early phase trials: A single-center retrospective analysis

4. 93P Evolving landscape of targeted therapies (TT) in early phase clinical trials (EPCT): The RESISTANCE project (360R)

5. 43P MDM2 alterations in primary brain tumors: A potential niche for targeted therapy

6. 250P Liver Toxicity (LT) in patients (pts) with ER-positive HER2-negative metastatic breast cancer (MBC) treated with first-line Cyclin-Dependent Kinase 4/6 inhibitors (CDKi)

7. 115P Longterm prognostic utility of 70-gene signature by clinical and genomic risks, including Ultralow (gUL) risk patients (pts)

8. 223P Tumor whole genome sequencing-based ultrasensitive ctDNA analysis as an early biomarker for clinical outcome in immune checkpoint inhibitor (ICI) phase I clinical trials (Ph1) and a tool for beyond progressive disease by iRECIST

10. 1479P Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study

12. 664P Impact of treatment beyond progression (TBP) in patients treated with immunotherapy (IO) in phase I trials (Ph1)

14. 457P Progression-free survival 2 (PFS2) as a surrogate for overall survival in a multicentric real-world data cohort of glioblastoma (GBM)

16. 503MO Real-world clinical and genomic characterization of gliomas: Predictive and prognostic insights

18. 2144P The PRognostic Oncologic Plantology (PROP) website tool predicts 30-day mortality in hospitalized cancer patients on treatment

20. 473P Predictive factors for drug-induced liver injury in patients with ER-positive HER2-negative metastatic breast cancer treated with first-line cyclin-dependent kinase 4/6 inhibitors

23. 686P Next generation sequencing (NGS) helps predict response to immunotherapy (IO) in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)

25. 290P Potential enrichment strategies for next-generation sequencing (NGS) in primary brain cancers (pBCs) in a clinical series according to ESMO scale for clinical actionability of molecular targets (ESCAT)

26. 126P The HLA I composite score and VHIO immune gene-expression signature (VIGex) as selection tools to explore the tumor microenvironment (TME) in patients (pts) treated with immunotherapy (IT)

27. 1724P Prognostic parameters at admission as predictors of hospital length of stay (HLOS) and overall survival (OS) in hospitalized oncologic patients (pts) of a tertiary hospital

29. 1431P Descriptive analysis and prognostic factors of microsatellite instability (MSI) gastric cancer patients (pts) compared to microsatellite stable (MSS) pts in a tertiary hospital

32. 1729P Influence of recent administration and type of oncological treatment (T) in survival of oncological patients (p) with COVID-19: Experience of Vall d’Hebron University Hospital

34. 1858P Role of depression and quality of life (QOL) status as predictors of hospital length of stay (HLOS) and overall survival (OS) in hospitalized oncologic patients (pts)

35. 938P Nutritional status (NS) as a strong predictor for immunotherapy (IT) outcome in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)

Catalog

Books, media, physical & digital resources